The Latest Cardiac and Vascular News
Collaboration Expands Access to AI Technologies for Early Detection and Personalized Treatment of Coronary Artery Disease SAN FRANCISCO, CA and DENVER, CO—[March 4, 2025]—Bunkerhill Health, a leader in AI-enabled early disease detection, and Cleerly, a pioneer in advanced cardiovascular imaging, announced today a strategic partnership to expand access to […]
December 4, 2024 (DENVER) – Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series C extension funding round, raising a total of $106 million. This funding round was led by global software investor Insight Partners and joined by Battery Ventures with participation from pre-existing investors. With this new funding, Cleerly will continue […]
Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care DENVER, Nov. 26, 2024 /PRNewswire/ — Cleerly, a leader in advanced cardiovascular imaging, is excited to announce its participation in the Radiological Society of North…
October 28, 2024 (DENVER) – Cleerly, a pioneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in […]
DENVER–(BUSINESS WIRE)–Several Medicare Administrative Contractors (MACs) have officially approved Artificial Intelligence-enabled Quantitative Coronary Topography (AI-QCT) scans for Medicare recipients with stable and acute symptoms suspicious of coronary artery disease. Cleerly, the company on a mission to eradicate heart attacks, requested the decision on MAC coverage in February of 2023 to expand […]
New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier SAN FRANCISCO – September 4, 2024 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Cleerly, the company working to create a new standard of care for the diagnosis of heart […]
DENVER–(BUSINESS WIRE)–Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. The study describes the validation of Cleerly’s artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification. In two trials,1-2
DENVER–(BUSINESS WIRE)–Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System. The CAD Staging System is a […]
DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Food and Drug Administration (FDA)-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram (CCTA) can be billed using the new Category I CPT® code 75580. The American […]
Study Results Demonstrate the Prominent Effects of Cleerly’s Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease DENVER – February 8, 2024 — Cleerly, the company working to create a new standard of care to aid in the diagnosis of heart disease, announced continued strong scientific evidence supporting […]
